- Home
- ATNM vs BTAI Comparison
ATNM vs BTAI Comparison
Compare ATNM & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATNM | BTAI |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.2M | 49.2M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | ATNM | BTAI |
|---|---|---|
| Price | $1.45 | $2.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $4.00 | ★ $32.80 |
| AVG Volume (30 Days) | 200.2K | ★ 625.0K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $90,000.00 | ★ $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $42,943.57 | $416.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.11 | N/A |
| 52 Week Low | $1.03 | $1.17 |
| 52 Week High | $2.41 | $9.26 |
Technical Indicators
Market Signals| Indicator | ATNM | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 50.45 | 54.05 |
| Support Level | $1.37 | $1.82 |
| Resistance Level | $1.54 | $2.30 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 55.17 | 72.20 |
Price Performance
Historical ComparisonAbout ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.